Effects of statins on microglia

Journal of Neuroscience Research

Volumn 82, Issue 1, 2005, Pages 10-19

  Lindberg, Catharina ^a,b   Crisby, Milita ^a   Winblad, Bengt ^a   Schultzberg, Marianne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

amyloid; Alzheimer's disease; Human; Interleukin; LPS

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; ATORVASTATIN; BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; SIMVASTATIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CELL ACTIVATION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN CELL; MICROGLIA; NERVE CELL CULTURE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT;

AMYLOID BETA-PROTEIN; ANIMALS; CELL DEATH; CELL LINE; CELL SURVIVAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; L-LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDES; MICROGLIA; PEPTIDE FRAGMENTS; PYRROLES; RATS; SIMVASTATIN; STATISTICS, NONPARAMETRIC; TETRAZOLIUM SALTS; THIAZOLES;

EID: 27744531727     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20615     Document Type: Article

References (61)

1. Adamson P, Greenwood J. 2003. How do statins control neuroinflammation? Inflamm Res 52:399-403.
2. Araujo DM, Cotman CW. 1992. β-Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res 569:141-145.
3. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM. 1999. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 96:15233-15238.
4. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, Yolk B, Berger M. 1991. Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 285: 111-114.
5. Bi X, Baudry M, Liu J, Yao Y, Fu L, Brucher F, Lynch G. 2004. Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. J Biol Chem 279:48238-48245 [Epub 42004 Sep 4823].
6. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. 2003. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63: 12-23.
7. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. 1995. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202:17-20.
8. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. 1985. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 76:1501-1513.
9. Caballero J, Nahata M. 2004. Do statins slow down Alzheimer's disease? A review. J Clin Pharmacol Ther 29:209-213.
10. Cacabelos R, Barquero M, Garcia P, Alvarez XA, Varela de Seijas E. 1991. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Methods Find Exp Clin Pharmacol 13:455-458.
11. Chauhan NB, Siegel GJ, Feinstein DL. 2004. Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRNDS brain. Neurochem Res 29:1897-1911.
12. Choi JW, Jung SE. 1999. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. J Pharmacol Exp Ther 289:572-579.
13. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. 2000. Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPAR γ agonists. J Neurosci 20:558-567.
14. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
15. Cordle A, Landreth G. 2005. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses. J Neurosci 25:299-307.
16. Del Bo R, Angeretti N, Lucca E, De Simoni MG, Forloni G. 1995. Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures. Neurosci Lett 188:70-74.
17. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. 1993. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7:75-83.
18. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. 2003. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J Cell Biol 160:113-123 [Epub 2003 Jan 2006].
19. Famer D, Crisby M. 2004. Rosuvastatin reduces caspase-3 activity and up-regulates α-secretase in human neuroblastoma SH-SY5Y cells exposed to Aβ. Neurosci Lett 371:209-214.
20. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. 2001. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A 98:5856-5861 [Epub 2001 Apr 5810].
21. Flavin MP, Ho LT. 1999. Propentofylline protects neurons in culture from death triggered by macrophage or microglial secretory products. J Neurosci Res 56:54-59.
22. Forloni G, Demicheli F, Giorgi S, Bendotti C, Angeretti N. 1992. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Brain Res Mol Brain Res 16:128-134.
23. Garcia-Roman N, Alvarez AM, Toro MJ, Montes A, Lorenzo MJ. 2001. Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol Cell Neurosci 17:329-341.
24. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL 3rd, Araoz C. 1989. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86:7611-7615.
25. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, Egido J. 1998. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83:490-500.
26. Heusinger-Ribeiro J, Fischer B, Goppelt-Struebe M. 2004. Differential effects of simvastatin on mesangial cells. Kidney Int 66:187-195.
27. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S. 2000. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPAR α) in primary endothelial cells. Life Sci 67:863-876.
28. Istvan E. 2003. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atherosclerosis Suppl 4:3-8.
29. Janabi N, Peudenier S, Heron B, Ng KH, Tardieu M. 1995. Establishment of human microglial cell lines after transfection of primary cultures of embryonic microglial cells with the SV40 large T antigen. Neurosci Lett 195:105-108.
30. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. 2000. Statins and the risk of dementia. Lancet 356:1627-1631.
31. Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, Kowala M. 2001. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol 1:105-118.
32. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. 2001. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Br Med J 322:1447-1451.
33. Kubota T, Fujisaki K, Itoh Y, Yano T, Sendo T, Oishi R. 2004. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol 67:2175-2186.
34. Kwak B, Mulhaupt F, Myit S, Mach F. 2000. Statins as a newly recognized type of immunomodulator. Nat Med 6:1399-1402.
35. Li JJ, Chen XJ. 2003. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis 14:329-334.
36. Lindberg C, Bardyl Selenica M-L, Westlind-Danielsson A, Schultzberg M. 2005a. β-amyloid structure determines the nature of cytokine release from rat microglia. J Mol Neurosci 27:1-12.
37. Lindberg C, Hjorth E, Post C, Winblad B, Schultzberg M. 2005b. Cytokine production by human microglia: effects of β-amyloid and α-melanocyte-stimulating hormone. Submitted for publication.
38. Matsumoto M, Einhaus D, Gold ES, Aderem A. 2004. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J Immunol 172:7377-7384.
39. McGeer PL, McGeer E, Rogers J, Sibley J. 1990. Anti-inflammatory drugs and Alzheimer disease. Lancet 335:1037.
40. McGeer PL, Schulzer M, McGeer EG. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47:425-432.
41. Michikawa M, Yanagisawa K. 1999. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J Neurochem 72:2278-2285.
42. Monick MM, Powers LS, Butler NS, Hunninghake GW. 2003. Inhibition of Rho family GTPases results in increased TNF-α production after lipopolysaccharide exposure. J Immunol 171:2625-2630.
43. Montero MT, Hernandez O, Suarez Y, Matilla J, Ferruelo AJ, Martinez-Botas J, Gomez-Coronado D, Lasuncion MA. 2000. Hydroxymethyl-glutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 153:303-313.
44. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L. 1992. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat Genet 1: 345-347.
45. Parvathy S, Ehrlich M, Pedrini S, Diaz N, Refolo L, Buxbaum JD, Bogush A, Petanceska S, Gandy S. 2004. Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. J Neurochem 90:1005-1010.
46. Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T, Duff K, Pappolla M, Refolo LM. 2002. Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 19:155-161.
47. Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB. 2004. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 295:245-257.
48. Rosenson RS, Tangney CC, Casey LC. 1999. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353:983-984.
49. Sadeghi MM, Collinge M, Pardi R, Bender JR. 2000. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol 165:2712-2718.
50. Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E, White JA, Bonnycastle L, Weber JL, Alonso ME, Potter H, Heston LL, Martin GM. 1992. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258:668-671.
51. Sjögren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, Wallin A, Blennow K. 2003. Treatment with simvastatin in patients with Alzheimer's disease lowers both α- and β-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 16:25-30.
52. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. 1993. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90:1977-1981.
53. Stüve O, Youssef S, Steinman L, Zamvil SS. 2003. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 16:393-401.
54. Sun D, Fernandes G. 2003. Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production. Cell Immunol 223:52-62.
55. 1-42 in glioma cell culture in vitro. Pharmacol Res 47:119-126.
56. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, Goodman SN. 2004. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23: 159-169.
57. Takahashi HK, Mori S, Iwagaki H, Yoshino T, Tanaka N, Weitz-Schmidt G, Nishibori M. 2005. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. J Leukoc Biol 77:400-407. [Epub 2004 Dec 2023].
58. Tarkowski E, Blennow K, Wallin A, Tarkowski A. 1999. Intracerebral production of tumor necrosis factor-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 19:223-230.
59. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443.
60. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC. 2005. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62:217-224.
61. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. 2002. Modulation of inflammatory mediators and PPAR γ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45:147-154.